FDA halts clinical trial enrolment for Gilead’s magrolimab in AML studies
According to Gilead Sciences, the screening and recruitment of new participants under the US Expanded Access Programme and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
22 Aug 23
According to Gilead Sciences, the screening and recruitment of new participants under the US Expanded Access Programme and…
22 Aug 23
Timber Pharmaceuticals' primary investigational product candidate, known as TMB-001, is a topical reformulation of isotretinoin, the active ingredient
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Aug 23
NeoMab is specifically designed to meet the burgeoning therapeutic antibody development demands of biotechnology companies and pharmaceutical enterprises
22 Aug 23
Study Reveals Potential for New AI-Based Tools to Transform Enzyme Design, Catalyzing Cell-Free Bioproduction Across Multiple Industries
21 Aug 23
Eylea is a vascular endothelial growth factor (VEGF) inhibitor that blocks the growth of new blood vessels in…
21 Aug 23
The sNDA is supported by the full data set from the Phase 3 randomised, double-blind, multicenter NefIgArd clinical…
18 Aug 23
Aquipta is a once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the prophylaxis of migraine in…
18 Aug 23
Coeptis gave Deverra around $570,000 in cash and 4,000,000 shares of its common stock for the immuno-oncology platform…
17 Aug 23
Sohonos is particularly selective for the gamma subtype of retinoic-acid receptors and mediates the interactions between the receptors,…
17 Aug 23
Under the agreement, US-based Eyenovia has obtained the exclusive US rights to distribute and sell APP13007 in a…